echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Over 300 billion Chinese medicine market, the era of big shuffling is coming!

    Over 300 billion Chinese medicine market, the era of big shuffling is coming!

    • Last Update: 2020-08-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    "Pharmaceutical Network Industry Dynamics" recently, Qinghai Province drug belt procurement open bid, in which the first appearance of Chinese medicine and Chinese medicine injections, including hi-yan flat injection, sputum heat-clearing injection, renal injection, blood plug-in tablets, blood plug-in particles, injection with thrombosis, dansan polyphenols, raw blood treasure particles, raw blood treasure and other large varieties.
    it is understood that the qinghai Province with a total of 59 varieties, 85 standards, are clinical use of large, procurement of high amount of drugs.
    in accordance with Qinghai requirements, each variety of drugs will have one enterprise to choose, 1 enterprise alternative.
    from the results, Chinese traditional medicine and omeprazole, such as the bargaining bid to be selected, for the limit price hanging network, without amount.
    although, to the particularity of traditional Chinese medicine, the industry is expected to compete more fully, the sale of high-value drugs or will be selected first, the probability of single varieties selected is not high, but, from the amount of procurement squeeze dry medicine price moisture, cut off the gold sales chain, forced the industry to purify and upgrade the original intention, the Chinese medicine super 300 billion market shuffle will eventually be in trouble.
    in fact, from the first batch of "4 plus 7" on November 14, 2018, to the third batch of national harvests in July 2020, the drugs selected were all chemicals and did not involve biological agents or traditional Chinese medicines.
    but with Qinghai, Liaoning, Zhejiang Jinhua and other places in the local version of the chinese drug belt procurement pilot has been launched, the local level of Chinese medicine, biological products tape procurement is becoming more aggressive.
    , such as according to Jinhua's second batch of pharmaceutical procurement public catalogue shows that its volume procurement involved a total of 274 drug regulations, including antibacterial drugs (non-original research) 70 standards, antibacterial drugs (original research) 24 standards, Chinese medicine (excluding low-cost drugs) 147 product regulations, Chinese traditional drugs (including low-cost drugs) 33 product regulations.
    Chinese medicine in addition to many varieties, there is no shortage of Qing Kailing particles, ginseng injection, dewind detoxified capsules and pedi-blue anti-inflammatory oral liquid and other well-known varieties of Chinese medicine.
    , the industry believes that the pilot experience in these areas may provide experience for larger-scale procurement of traditional Chinese medicine belt in the future.
    in fact, the national version of traditional Chinese medicine with the volume of procurement work, in the near future has begun to show the show.
    July 15-16, the relevant departments of the State Medical Security Administration have held a symposium to listen to expert opinions and suggestions on the centralized procurement of biological products (including insulin) and traditional Chinese medicine, to study and improve procurement policies in related fields, and to promote the reform of procurement methods.
    to this, some industry insiders believe that this may mean that biopharmaceuticals and traditional Chinese medicine will be included in the collection, it is possible that in the future China's fourth batch of centralized procurement will be biological drugs and traditional Chinese medicine into it.
    in addition, the industry also believes that if the Chinese medicine is also included in the centralized procurement of the country, will have a huge impact on the market pattern of traditional Chinese medicine, the full competition of large amounts of traditional Chinese medicine is likely to become the focus of procurement.
    the fate of future traditional Chinese medicines that do not prove their safety and efficacy in a timely manner, or that they will be eliminated at an accelerated rate.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.